Plain-English translation of NCT07743164 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ovarian Cancer research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a new medication called raludotatug deruxtecan () to see if it can help people with advanced ovarian cancer whose cancer has started growing again after initial treatment with PARP inhibitors. The medication is designed to find and attack cancer cells directly. Researchers want to know if this treatment—given alone or combined with another drug called —works better than standard chemotherapy at slowing cancer growth and helping people live longer.
Many people with advanced ovarian cancer develop resistance to PARP inhibitors, a common maintenance treatment, and their cancer starts growing again. Doctors need better options for these patients, and this medication is a new approach designed to target cancer cells more precisely.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to receive either the new medication (with or without ) given through an IV, or standard chemotherapy (with or without ). Treatment will continue for up to 2 years, unless your cancer grows, you experience unacceptable side effects, or other reasons require stopping. You'll have regular clinic visits and scans to monitor how well the treatment is working and how you're tolerating it.
AI-generated summary from trial data · Oct 22, 2026 · Not medical advice
United States
Israel